[go: up one dir, main page]

KR950704482A - 치료용 항-hiv 올리고누클레오티드 및 이것을 함유하는 약제학적 제형(therapeutic anti-hiv oligonucleotide and pharmaceutical) - Google Patents

치료용 항-hiv 올리고누클레오티드 및 이것을 함유하는 약제학적 제형(therapeutic anti-hiv oligonucleotide and pharmaceutical)

Info

Publication number
KR950704482A
KR950704482A KR1019950701317A KR19950701317A KR950704482A KR 950704482 A KR950704482 A KR 950704482A KR 1019950701317 A KR1019950701317 A KR 1019950701317A KR 19950701317 A KR19950701317 A KR 19950701317A KR 950704482 A KR950704482 A KR 950704482A
Authority
KR
South Korea
Prior art keywords
oligonucleotide
hiv
seq
nucleotides
sequence listing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019950701317A
Other languages
English (en)
Inventor
아그라월 서드허
얀 탕 진
Original Assignee
다알렌 반스톤
하이브리돈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다알렌 반스톤, 하이브리돈 인코포레이티드 filed Critical 다알렌 반스톤
Publication of KR950704482A publication Critical patent/KR950704482A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

본 발명에서는 HIV-1게놈의 보존된

Description

치료용 항-HIV 올리고누클레오티드 및 이것을 함유하는 약제학적 제형(THERAPEUTIC ANTI-HIV OLIGONUCLEOTIDE AND PHARMACEUTICAL)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 HIV-1 게놈의 표적화된개시 영역 및 그것에 대한 본 발명의 안티센스 포스포티오에이트 누클레오티드의 상보성을 도시한 개략도,
제2도는 표적화된개시 영역 및 본 발명의 25합체를 도시하는 개략도,
제3도는 표적화된개시 영역 및 미츠쿠라등의 28합체를 도시한 개략도.

Claims (24)

  1. 최소한 하나의 비-포스포디에스테르 누클레오티드간 결합에 의해 결합된 약 25 내지 30누클레오티드를 가지며, 이 결합으로 인해 누클레아제 소화에 대해 올리고 누클레오티드가 내성을 갖게 되는, HIV-1 게놈의 보존된영역의 최소한의 누클레오티드 324 내지 348에 혼성화하는 누클레오티드 서열을 갖고 있는 올리고누클레오티드.
  2. 제1항에 있어서, 리소한 하나의 비-포스포디에스테르 누클레오티드간 결합이 포스포로티오에이트 결합인 것을 특징으로 하는 올리고누클레오티드.
  3. 제2항에 있어서, 올리고누클레오티드가 25개의 누클레오티드를 가지는 것을 특징으로 하는 올리고누클레오티드.
  4. 제3항에 있어서, 서열 목록에서 SEQ ID NO : 1로서 표시된 누클레오티드를 가지는 올리고누클레오티드.
  5. 제2항에 있어서, 올리고누클레오티드가 26개의 누클레오티드를 가지는 것을 특징으로 하는 올리고누클레오티드.
  6. 제5항에 있어서, 서열 목록에서 SEQ ID NO : 2로서 표시된 누클레오티드 서열을 가지는 올리고누클레오티드.
  7. 제5항에 있어서, 서열 목록에서 SEQ ID NO : 3으로서 표시된 누클레오티드 서열을 가지는 올리고누클레오티드.
  8. 제2항에 있어서, 올리고누클레오티드가 27개의 누클레오티드들 가지는 것을 특징으로 하는 올리고누클레오티드.
  9. 제8항에 있어서, 서열 목록에서 SEQ ID NO : 4로서 표시된 누클레오티드 서열을 가지는 올리고누클레오티드.
  10. 제2항에 있어서, 올리고누클레오티드가 28개의 누클레오티드를 가지는 것을 특징으로 하는 을리고누클레오티드.
  11. 제10항에 있어서, 서열 목록에서 SEQ ID NO : 5로서 표시된 누클레오티드 서열을 가지는 올리고누클레오티드.
  12. 제10항에 있어서, 서열 목록에서 SEQ ID NO : 6로서 표시된 누클레오티드 서열을 가지는 올리고누클레오티드.
  13. 제2항에 있어서, 올리고누클레오티드가 29개의 누클레오티드를 가지는 것을 특징으로 하는 올리고누클레오티드.
  14. 제13항에 있어서, 서열 목록에서 SEQ ID NO : 7로서 표시된 누클레오티드 서열을 가지는 올리고누클레오티드.
  15. 제2항에 있어서, 올리고누클레오티드가 30개의 누클레오티드를 가지는 것을 특징으로 하는 올리고누클레오티드.
  16. 제15항에 있어서, 서열 목록에서 SEQ ID NO : 8로서 표시된 누클레오티드 서열을 가지는 올리고누클레오티드.
  17. 제15항에 있어서, 서열 목록에서 SEQ ID NO : 9로서 표시된 누클레오티드 서열을 가지는 올리고누클레오티드.
  18. 생리적으로 허용되는 담체중에 제1항의 올리고누클레오티드를 포함하는 치료용 제형.
  19. 생리적으로 허용되는 담체중에 제4항의 올리고누클레오티드클 포함하는 치료용 제형.
  20. 제1항의 올리고누클레오티드인 제1의 올리고누클레오티드와 제2의 항-HIV-1 안티센스 올리고누클레오티드를 포함하는 치료용 제형.
  21. (a)생리적으로 허용되는 담체중에 제1항의 올리고누클레오티드를 포함하는 치료용 제형을 제공하는 단계 ; 그리고 (b)HIV-1 감염된 세포를, 감염된 세포에서 어떠한 HIV-1 프로바이러스 DNA 또는 mRNA의영역에 올리고누클레오티드가 결합되는 것을 가능하게 하기에 충분한 양의 치료용 제형으로 처리하는 단계로 이루어지며, 그로써, 올리고누클레오티드가 HIV-1 DNA또는 mRNA에 결합하여 HIV-1의 증식이 억제되는 것을 특징으로 하는, HIV-1 증식의 억제 방법.
  22. 제21항에 있어서, 상기 제공 단계가 최소한 하나의 포스포로티오에이트 결합에 의해 결합된 25개의 누클레오티드를 갖는 올리고누클레오티드를 제공하는 것을 포함하며, 올리고누클레오티드의 서열은 서열 목록에서 SEQ ID NO : 1로서 표시되는 것을 특징으로 하는 방법.
  23. (a)생리적으로 허용되는 담체중에 제1항의 올리고누클레오티드틀 포함하는 치료용 제형을 제공하는 단계 ; 그리고 (b)HIV-1 감염된 세포를, 감염된 세포에서 어떠한 HIV-1 프로바이러스 DNA 또는 mRNA의영역에 올리고누클레오티드가 결합하는 것을 가능하게 하기에 충분한 양의 치료용 제형으로 처리하는 단계로 이루어지며, 그로써, 올리고누클레오티드가 HIV-1 DNA 또는 mRNA에 결합하여 포유류에서 HIV-1 DNA의 발현 및 복제가 억제되는 것을 특징으로 하는, 포유류에서 HIV-1 감염을 치료하는 방법.
  24. 제23항에 있어서, 상기 제공 단계가 최소한 하나의 포스포로티오에이트 결합에 의해 결합된 25개의 누클레오티드를 갖는 올리고누클레오티드를 제공하는 것을 포함하며, 올리고누클레오티드의 서열은 서열 목록에서 SEQ ID NO : 1로서 표시되는 것을 특징으로 하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950701317A 1992-10-05 1993-10-04 치료용 항-hiv 올리고누클레오티드 및 이것을 함유하는 약제학적 제형(therapeutic anti-hiv oligonucleotide and pharmaceutical) Withdrawn KR950704482A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95813592A 1992-10-05 1992-10-05
US958135 1992-10-05
PCT/US1993/009392 WO1994008004A1 (en) 1992-10-05 1993-10-04 Therapeutic anti-hiv oligonucleotide and pharmaceutical

Publications (1)

Publication Number Publication Date
KR950704482A true KR950704482A (ko) 1995-11-20

Family

ID=25500631

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950701317A Withdrawn KR950704482A (ko) 1992-10-05 1993-10-04 치료용 항-hiv 올리고누클레오티드 및 이것을 함유하는 약제학적 제형(therapeutic anti-hiv oligonucleotide and pharmaceutical)

Country Status (19)

Country Link
US (1) US5684147A (ko)
EP (1) EP0664833B1 (ko)
JP (1) JPH08504570A (ko)
KR (1) KR950704482A (ko)
AT (1) ATE146819T1 (ko)
AU (1) AU678415B2 (ko)
BR (1) BR9307191A (ko)
CA (1) CA2146364A1 (ko)
CZ (1) CZ85495A3 (ko)
DE (1) DE69306969T2 (ko)
DK (1) DK0664833T3 (ko)
ES (1) ES2096343T3 (ko)
FI (1) FI951600A7 (ko)
GR (1) GR3022315T3 (ko)
HU (1) HUT72400A (ko)
NO (1) NO951307L (ko)
NZ (1) NZ257434A (ko)
PL (1) PL308261A1 (ko)
WO (1) WO1994008004A1 (ko)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US5733781A (en) * 1994-07-19 1998-03-31 Gen-Probe Incorporated Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
RU2136752C1 (ru) * 1997-05-22 1999-09-10 Государственный научный центр вирусологии и биотехнологии "Вектор" Способ ингибирования репродукции вируса иммунодефицита человека
US6610539B1 (en) * 1997-07-10 2003-08-26 Genesense Technologies, Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
EP1584681A3 (en) * 1997-07-10 2005-11-09 GeneSense Technologies Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
WO1999009154A2 (en) 1997-08-19 1999-02-25 Hybridon, Inc. Novel hiv-specific synthetic oligonucleotides and methods of their use
JP2002516294A (ja) 1998-05-22 2002-06-04 ローブ ヘルス リサーチ インスティチュート アット ザ オタワ ホスピタル 粘膜免疫を誘導するための方法および産物
AU772847B2 (en) 1998-11-12 2004-05-06 Invitrogen Corporation Transfection reagents
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
JP4824236B2 (ja) * 1999-07-09 2011-11-30 ジェン−プローブ・インコーポレーテッド 核酸増幅によるｈｉｖ−１の検出
AU780116B2 (en) * 1999-12-23 2005-03-03 Board Of Regents, The University Of Texas System Inhibition of cellular proteases
WO2001051500A1 (en) * 2000-01-14 2001-07-19 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6582920B2 (en) * 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
JP2002125687A (ja) * 2000-10-30 2002-05-08 Tosoh Corp Ｈｉｖ−１検出のためのオリゴヌクレオチドおよび検出法
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US7354909B2 (en) 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
SG177000A1 (en) 2001-08-17 2012-01-30 Coley Pharm Gmbh Combination motif immune stimulatory oligonucleotides with improved activity
US7615227B2 (en) 2001-12-20 2009-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce angiogenesis
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
PT2241325E (pt) 2002-10-29 2012-04-12 Coley Pharm Gmbh Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
EP1627563A1 (en) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for producing a stabilized cell of interest
EP1647595A1 (en) * 2004-10-15 2006-04-19 Academisch Medisch Centrum bij de Universiteit van Amsterdam Nucleic acids against viruses, in particular HIV
US8399423B2 (en) * 2005-10-12 2013-03-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
USRE49583E1 (en) 2005-11-17 2023-07-18 Tet Systems Gmbh & Co. Kg Inducible expression systems
ATE512228T1 (de) 2005-11-17 2011-06-15 Tet Systems Gmbh & Co Kg Induzierbare expressionssysteme
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
PT2540820T (pt) 2005-12-09 2018-03-02 Academisch Medisch Centrum Bij De Univ Van Amsterdam Meios e métodos para influenciar a establidade de células produtoras de anticorpos
AU2010271583B2 (en) 2009-07-15 2015-02-12 Kling Biotherapeutics B.V. Means and methods for producing high affinity antibodies
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CN103429615B (zh) 2010-12-02 2018-03-16 埃姆医疗有限公司 用于生产高亲和力抗体的方式和方法
LT2691530T (lt) 2011-06-10 2018-08-10 Oregon Health & Science University Cmv glikoproteinai ir rekombinantiniai vektoriai
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US9932364B2 (en) 2013-08-26 2018-04-03 The Royal Institution For The Advancement Of Learning/Mcgill University Antisense-based small RNA agents targeting the Gag open reading frame of HIV-1 RNA
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
JP6747975B2 (ja) 2014-01-31 2020-08-26 アイム・セラピューティクス・べー・フェー 安定な抗体を産生するための手段及び方法
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0331939B1 (en) * 1988-02-16 2001-11-14 Greatbatch Gen-Aid, Ltd Modified cells having resistance to retroviral infection
JPH04501052A (ja) * 1988-02-26 1992-02-27 ザ・ウスター・フアウンデーシヨン・フオー・バイオメデイカル・リサーチ 外来性オリゴヌクレオチドによるｈｔｌｖ―３の抑制

Also Published As

Publication number Publication date
ATE146819T1 (de) 1997-01-15
FI951600A0 (fi) 1995-04-04
HU9500995D0 (en) 1995-06-28
DE69306969D1 (de) 1997-02-06
PL308261A1 (en) 1995-07-24
EP0664833B1 (en) 1996-12-27
BR9307191A (pt) 1999-03-30
HUT72400A (en) 1996-04-29
US5684147A (en) 1997-11-04
NO951307D0 (no) 1995-04-04
WO1994008004A1 (en) 1994-04-14
CZ85495A3 (en) 1996-03-13
DK0664833T3 (da) 1997-04-14
DE69306969T2 (de) 1997-05-07
AU5402894A (en) 1994-04-26
EP0664833A1 (en) 1995-08-02
NO951307L (no) 1995-06-01
FI951600L (fi) 1995-05-10
GR3022315T3 (en) 1997-04-30
CA2146364A1 (en) 1994-04-14
FI951600A7 (fi) 1995-05-10
AU678415B2 (en) 1997-05-29
NZ257434A (en) 1997-01-29
ES2096343T3 (es) 1997-03-01
JPH08504570A (ja) 1996-05-21

Similar Documents

Publication Publication Date Title
KR950704482A (ko) 치료용 항-hiv 올리고누클레오티드 및 이것을 함유하는 약제학적 제형(therapeutic anti-hiv oligonucleotide and pharmaceutical)
Giles et al. Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures
US5567604A (en) Anti-viral guanosine-rich oligonucleotides
Iwai et al. Recognition of the high affinity binding site in rev-response element RNA by the human immunodeficiency virus type-1 rev protein
KR930701466A (ko) 안티센스 올리고뉴클레오티드에 의한 a형 인플루엔자 바이러스, 안 아아보 스트레인(ann arbor strain)h2n2의 억제
Pritchard et al. Methylphosphonate mapping of phosphate contacts critical for RNA recognition by the human immunodeficiency virus tat and rev proteins
Cohen Antisense oligodeoxynucleotides as antiviral agents
KR960701077A (ko) 올리고누클레오티드 알킬포스포네이트 및 알킬포스포노티오에이트(oligonucleotide alkylphosphonates and alkylphosphonothioates)
Boulmé et al. Modified (PNA, 2′-O-methyl and phosphoramidate) anti-TAR antisense oligonucleotides as strong and specific inhibitors of in vitro HIV-1 reverse transcription
WO1999009154A3 (en) Novel hiv-specific synthetic oligonucleotides and methods of their use
AU1647095A (en) Therapeutic ribozyme compositions
KR960704033A (ko) 인간 면역결핍 바이러스에 대한 활성을 갖는 올리고뉴클레오티드(Oligonucleotides with Activity against Humand Immunodeficiency Virus)
CA2494930A1 (en) Modified forms of interfering rna molecules
RU2020115761A (ru) МОЛЕКУЛЫ НУКЛЕИНОВЫХ КИСЛОТ ДЛЯ УМЕНЬШЕНИЯ УРОВНЯ мРНК PAPD5 ИЛИ PAPD7 ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИОННОГО ГЕПАТИТА В
FR2790757B1 (fr) Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
US8779113B2 (en) Group of nucleic acid fragments for prevention of HIV infection or AIDS and the usage thereof
Agrawal et al. Phosphoramidate, phosphorothioate, and methylphosphonate analogs of oligodeoxynucleotide: inhibitors of replication of human immunodeficiency virus
Inagawa et al. Inhibition of human immunodeficiency virus type 1 replication by P‐stereodefined oligo (nucleoside phosphorothioate) s in a long‐term infection model
Tonkinson et al. Antisense nucleic acids—prospects for antiviral intervention
RU2008130901A (ru) iPHK-ОПОСРЕДОВАНННОЕ ИНГИБИРОВАНИЕ IGFR ДЛЯ ЛЕЧЕНИЯ ГЛАЗНОГО АНГИОГЕНЕЗА
WO1996023878A1 (en) Human immunodeficiency virus transcription inhibitors and methods of their use
PRASEUTH et al. Unexpected effect of an anti-human immunodeficiency virus intermolecular triplex-forming oligonucleotide in an in vitro transcription system due to RNase H-induced cleavage of the RNA transcript
AU2001284570A1 (en) New sequences
WO2002016608A1 (en) New sequences
Dukhan et al. 4′-Thio-RNA: Synthesis, Base Pairing Properties and Interaction with Dimerization Initiation Site of HIV-1

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19950406

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid